Glucagon-like peptide-1 GLP-1 is a naturally occurring 30-amino acid peptide synthesised in intestinal endocrine L cells. GLP-1 mediates glucose homeostasis through stimulation of glucose-dependent insulin secretion, biosynthesis of insulin and inhibition of glucagon secretion. These effects have potential clinical value in type 2 diabetes. However, because native GLP-1 is rapidly degraded to its inactive form by dipeptidyl peptidase-4 (DPP-4), it has a short half-life in vivo . Strategies to overcome this therapeutic limitation include developing GLP-1 mimetics and analogues with longer half-lives and to inhibit DPP-4. Exenatide (exendin-4) is a 39-amino acid peptide originally derived from the venom of the Gila monster lizard, and shares a 53% sequence identity with human GLP-1. Exenatide has a longer circulating half-life, reflecting relative resistance to DPP-4 degradation, and is administered twice daily. Liraglutide is a once-daily human GLP-1 analogue with high (97%) sequence identity. The specific structural modifications that characterise liraglutide result in increased self-association (allowing slow absorption from the subcutaneous depot), promote albumin binding and reduce susceptibility to DPP-4, giving liraglutide a half-life of 13 hours after once-daily administration. Preliminary studies of exenatide and liraglutide show clinically relevant reductions in glycosylated haemoglobin A1c (HbA1c) compared with placebo, without hypoglycaemia and with weight loss of up to 3 kg. DPP-4 inhibitors, such as vildagliptin (not available in the USA) and sitagliptin can help stabilise postprandial GLP-1 levels and thus produce desirable effects on insulin and glucagon production. The potential for weight reduction with DPP-4 inhibitors appears limited, perhaps reflecting the limited increase in GLP-1 levels achieved with these agents.Br J Diabetes Vasc Dis, 2008;8 (Suppl 2) : S10—S18
Holst JJ, Bersani M., Johnsen AH et al. Proglucagon processing in porcine and human pancreas. J Biol Chem1994;269:18827-33.
2.
Chen YE, Drucker DJTissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem1997;272:4108-15.
3.
Mojsov S., Heinrich G., Wilson IB et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem1986;261:11880-9.
rskov C., Bersani M., Johnsen AH et al. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem1989;264:12826-9.
6.
Holst JJThe physiology of glucagon-like peptide 1. Physiol Rev2007;87:1409-39.
7.
Buhl T., Thim L., Kofod H. et al. Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J Biol Chem1988 ;263:8621-4.
8.
rskov C., Buhl T., Rabenhøj L. et al. Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine. FEBS Lett1989;247:193-6.
9.
Kervran A., Blache P., Bataille D.Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat. Endocrinology1987;121:704-13.
10.
Drucker DJEnhancing incretin action for the treatment of type 2 diabetes. Diabetes Care2003;26:2929-40.
11.
Ahrén B.Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep2003;3:365-72.
12.
Drucker DJBiological actions and therapeutic potential of the glucagon-like peptides . Gastroenterology2002;122:531-44.
13.
Farilla L., Bulotta A., Hirshberg B. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology2003;144:5149-58.
14.
Trümper A., Trümper K., Trusheim H. et al. Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol Endocrinol2001;15:1559-70.
15.
Trümper A., Trümper K., Hörsch D.Mechanisms of mitogenic and antiapoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells. J Endocrinol2002;174:233-46.
16.
Wideman RD, Kieffer TJGlucose-dependent insulinotropic peptide as a regulator of beta cell function and fate. Horm Metab Res2004; 36:782-6.
17.
Nauck MA, Niedereichholz U., Ettler R. et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab1997;273:981-8.
18.
Tourrel C., Bailbe D., Meile MJ et al. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenisis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes2001;50:1562-70.
19.
Perfetti R. , Zhou J., Doyle ME, Egan JMGlucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose intolerant rats. Endocrinology2000;141:4600-5.
20.
Farilla L., Hui H., Bertolotto C. et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology2002;143:4397-408.
21.
Meier JJ, Goetze O., Anstipp J. et al. Gastric inhibitory peptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab2004 ;286:E621-5.
22.
Nauck MA, Heimesaat MM, rskov C. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest1993;91:301-7.
23.
Vilsbøll T., Holst JJIncretins, insulin secretion and type 2 diabetes mellitus. Diabetologia2004;47:357-66.
24.
rskov C., Wettergren A., Holst JJSecretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol1996;31:665-70.
25.
Vilsbøll T., Krarup T., Madsbad S., Holst JJBoth GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept2003;114:115-21.
26.
Toft-Nielsen M-B., Damholt MB, Madsbad S. et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab2001;86:3717-23.
27.
Vilsbøll T. , Krarup T., Madsbad S., Holst JJDefective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia2002;45:1111-9.
28.
Elahi D., McAloon-Dyke M., Fukagawa NK et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept1994;51:63-74.
29.
Højberg PV, Visbøl T., Bache M. et al. Incretin effects: clinical. 43rd European Association for the Study of Diabetes Annual Meeting, 17-21 September 2007, Amsterdam, The Netherlands. Abstract OP45.
30.
Zander M., Madsbad S., Madsen JL, Holst JJEffect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and βcell function in type 2 diabetes: a parallel-group study . Lancet2002;359:824-30.
31.
Buteau, J., Roduit R., Susini S., Prentki M.Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia1999;42:856-64.
32.
Buteau J., El-Assaad W., Rhodes CJ et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity . Diabetologia2004;47:806-15.
33.
Verdich C., Flint A., Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab2001;86:4382-9.
34.
Bullock BP, Heller RS, Habener JFTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology1996;137:2968-78.
35.
Fortuin NJ, Hood WP Jr, Craige E.Evaluation of left ventricular function by echocardiography. Circulation1972;46:26-35.
36.
Gros R., You X., Baggio LL et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology2003;144:2242-52.
37.
Yu M., Moreno C., Hoagland KM et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens2003;21:1125-35.
38.
Nikolaidis LA, Elahi D., Hentosz T. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation2004;110:955-61.
39.
Bose AK, Mocanu MM, Carr RD et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes2005 ;54:146-51.
40.
Nikolaidis LA, Mankad S., Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation2004;109:962-5.
41.
Nyström T., Gutniak MK, Zhang Q. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab2004;287:E1209-15.
42.
Deacon CF, Johnsen AH, Holst JJDegradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo . J Clin Endocrinol Metab1995;80:952-7.
43.
Vilsbøll T. , Agersø H., Krarup T., Holst JJSimilar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab2003;88:220-4.
44.
Eng J., Kleinman WA, Singh L. et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem1992;267:7402-5.
45.
Drucker DJThe biology of incretin hormones. Cell Metab2006;3:153-65.
46.
Kolterman OG , Kim DD, Shen L. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm2005;62:173-81.
Kim D., MacConell L., Zhuang D. et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes . Diabetes Care2007;30:1487-93.
49.
Buse JB, Henry RR, Han J. et al. For the Exenatide-113 Clincial Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care2004;27:2628-35.
50.
DeFronzo RA , Ratner RE, Han J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care2005;28:1092-100.
51.
Kendall DM, Riddle MC, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea . Diabetes Care2005;28:1083-91.
52.
Blonde L., Klein EJ, Han J. et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab2006;8:436-47.
53.
Holst JJTreatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs2004;9:155-66.
54.
Agersø H., Jensen LB, Elbrønd B. et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia2002;45:195-202.
55.
Elbrønd B., Jakobsen G., Larsen S. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care2002 ;25:1398-404.
56.
Chang AM, Jakobsen G., Sturis J. et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes2003;52:1786-91.
57.
Choukem SP, Gautier J-F. How do different GLP-1 mimetics differ in their actions? Curr Diab Rep2006;6:365-72.
58.
Feng J., Zhang Z., Wallace MB et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem2007;50:2297-300.
59.
Amori RE, Lau J., Pittas AGEfficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA2007;298:194-206.
60.
Nauck MA, Meininger G., Sheng D. et al. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab2007;9:194-205.
61.
Rosenstock J. , Baron MA, Dejager S. et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. A 24-week, double-blind, randomized trial. Diabetes Care2007; 30:217-23.
62.
Rosenstock J. , Kim SW, Baron MA et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab2007;9:175-85.
63.
Schweizer A. , Couturier A., Foley JE, Dejager S.Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med2007; 24:955-61.
